Clinical Trial Search

Primary: Independent Review Facility (IRF)-Assessed Progression-Free Survival (PFS) — 5.39; 6.18 months — p=<0.0001

Primary: Percentage of Participants Achieving at Least 90% Reduction in Plasmodium Falciparum (P. Falciparum) at 12 Hours — 80.0; 93.0; 39.3 percentage of participants

Primary: Number of Participants With Hypoglycemia During Postpartum Hospital Stay — 5; 2; 4; 5 participants

Primary: Untrimmed Airway Volume (siVaw) for Distal Region at Total Lung Capacity (TLC) - Actual Value for V2 Pre-dose and V3 Pre-dose — 1.4088; 1.3550 liters — p== 0.4521

Primary: The Hospital Anxiety and Depression Scale (HADS) - Anxiety Subscale — 10.32; 8.26; 8.96 units on scale

Primary: Parent Global Impressions of Autism - Change — 0.36 score on a scale

Primary: Actigraphy-derived Sleep Efficiency (SE) Percentage — 74.89; 69.47; 66.67; 71.04 % of time asleep in bed/night

Primary: Change in Adolescent Abdominal Pain Severity — 2.11; 1.74; 1.99; 1.61 scores on a scale

Primary: Deep Dyspareunia Score — 3.08 scores on a scale

Primary: Safety of High-Purity Type I Collagen Augmentation — 0; 0; 0; 0 Participants

Primary: Vineland-3 Adaptive Behavior Composite Score — 74.8; 87.5; 90.8 units on a scale — p=<0.001

Primary: Primary Analysis: Overall Minimal Residual Disease (MRD) Negative Rate — 35.4; 53.3 Percentage of participants — p==0.0004

Primary: Change in Asthma-related Quality of Life (Mini AQLQ Score) - 12 Months — 0.34; 0.11 Change in units on a scale

Primary: Safety/Tolerability (Adverse Events) — 9; 9 Participants

Primary: ORR — 15; 8; 2 Participants